CASP5 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL1123752	0.78	10/20
SCHEMBL2772556	0.61	9/20
SCHEMBL2773410	0.56	8/20
SCHEMBL2813450	0.50	8/20
Tirilazad (SCHEMBL483318)	0.79	7/20
SCHEMBL1091086	0.71	7/20
SCHEMBL1124029	0.61	7/20
SCHEMBL2771547	0.59	7/20
SCHEMBL2807024	0.55	7/20
SCHEMBL2808318	0.54	7/20
Hydrochloric Acid (SCHEMBL3092488)	0.54	7/20
SCHEMBL2808295	0.49	5/20
SCHEMBL2744129	0.54	4/20
SCHEMBL2807168	0.51	4/20
SCHEMBL2773991	0.49	4/20
Tirilazad (SCHEMBL1650168)	0.74	3/20
Tirilazad (SCHEMBL49410)	0.73	3/20
SCHEMBL2744127	0.50	3/20
Hydrochloric Acid (SCHEMBL1527766)	0.84	2/20
Hydrochloric Acid (SCHEMBL1527767)	0.74	2/20

Clinical trials — most relevant to CASP5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?	PHASE4	COMPLETED
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Disulfiram in Rheumatoid Arthritis	PHASE2	NOT_YET_RECRUITING
Atorvastatin Calcium, Oligofructose-Enriched Inulin, or Sulindac in Preventing Cancer in Patients at Increased Risk of Developing Colorectal Neoplasia	PHASE2	COMPLETED
A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension	PHASE2	COMPLETED
Safety, Tolerability, and Treatment Effect of Belnacasan in Patients With COVID-19	PHASE2	COMPLETED
Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation	PHASE2	COMPLETED
Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival	PHASE1	UNKNOWN
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma	PHASE1	RECRUITING
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure	nan	RECRUITING
Circulating Markers for Ischemic Heart Disease	nan	RECRUITING
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Characterization of Non-canonical Way in Inflammasome Monocytes of Patients With Severe Sepsis	nan	COMPLETED
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients	nan	UNKNOWN
Impact of CASP3 Gene in Chemoresistance	nan	NOT_YET_RECRUITING
Analysis of the Variation in Caspase-8 Availability and Cleavage in Oral Squamous Cell Carcinoma	nan	UNKNOWN
New Signaling Pathway Targeting Systemic Lupus Erythematosus	nan	UNKNOWN
Role of Serum ADAM 17 (A Disintegrin And Metalloprotease 17) and Caspase 3 in Patients With Chronic Kidney Disease	nan	NOT_YET_RECRUITING
Inflammasomes in Cell Death in FTMH, ERM, and RRD	nan	COMPLETED
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases	nan	UNKNOWN
Apoptosis May Have a Role in Etiopathogenesis of Obstetric Cholestasis.	nan	UNKNOWN
Patient-Derived Organoids to Functionally Characterize Chemotherapy Resistance in Breast Cancer	nan	NOT_YET_RECRUITING
The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT	nan	UNKNOWN
Role NLRP3 Inflammasome in Weight Loss Following Sleeve Gastrectomy in Morbidly Obese Patients	nan	UNKNOWN
The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1β Secretion by Mononuclear	nan	UNKNOWN
Genetic Determinants of Sudden Cardiac Death	nan	COMPLETED
Early Diagnosis and Prognosis of Postoperative Sepsis by Presepsin and Syndecan-1	nan	UNKNOWN
Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)	nan	COMPLETED
Autophagy Bladder Cancer	nan	UNKNOWN
The Role of Pyroptosis in Chronic Venous Disease	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a CASP5 binder may also engage these)

Protein	Name	Similarity
Q153Z0	—	0.989	Q153Z0 →
O08736	—	0.985	O08736 →
Q920D5	—	0.984	Q920D5 →
Q075B4	—	0.984	Q075B4 →
P70343	—	0.983	P70343 →
CASP12	Inactive caspase-12 (CASP-12)	0.982	landscape →
P29452	—	0.976	P29452 →
P43527	—	0.972	P43527 →
CASP4	Caspase-4	0.966	landscape →
O75601	—	0.961	O75601 →
O35368	—	0.957	O35368 →
Q16666	—	0.956	Q16666 →
Q8SPH9	—	0.955	Q8SPH9 →
Q5E9C1	—	0.954	Q5E9C1 →
P41218	—	0.953	P41218 →
P0DOV2	—	0.952	P0DOV2 →
Q5RD14	—	0.952	Q5RD14 →
B0FPE9	—	0.951	B0FPE9 →
Q8CGE8	—	0.950	Q8CGE8 →
NLRP3	NACHT, LRR and PYD domains-containing protein 3	0.949	landscape →
SLFN12	Ribonuclease SLFN12	0.947	landscape →
Q5D7I6	—	0.947	Q5D7I6 →
Q3UX83	—	0.947	Q3UX83 →
Q8BV49	—	0.947	Q8BV49 →
Q9I9L7	—	0.947	Q9I9L7 →
Q62929	—	0.947	Q62929 →
Q504N7	—	0.946	Q504N7 →
Q2LKU9	—	0.946	Q2LKU9 →
Q5D7H7	—	0.945	Q5D7H7 →
Q7RTR0	—	0.945	Q7RTR0 →